Penetrating keratoplasty for pseudophakic bullous keratopathy. Visual results

Archives of Ophthalmology
S R Waltman

Abstract

Thirty-six patients with pseudophakic bullous keratopathy had penetrating keratoplasties with one immediate graft failure and two subsequent rejections. Fifty-four percent of the patients saw 20/40 or better, and 79% saw 20/80 or better. These results are much better than reported for aphakic bullous keratopathy. Endothelial counts in the other eyes showed that 17% of these patients have unexpectedly very low cell counts, which were not appreciated on slitlamp examination and were probably a contributing factor to their corneal decompensation.

Citations

Jul 15, 1988·American Journal of Ophthalmology·M S InslerH E Kaufman
Mar 1, 1989·Ophthalmic Surgery·L K Morrison, S R Waltman
Sep 15, 1984·American Journal of Ophthalmology·D J SchanzlinR E Smith
May 15, 1985·American Journal of Ophthalmology·P S Binder
Jul 15, 1985·American Journal of Ophthalmology·S G Kramer
May 1, 1995·The British Journal of Ophthalmology·J KwartzA B Tullo
Aug 1, 1990·Australian and New Zealand Journal of Ophthalmology·A M BrooksW E Gillies
Jan 1, 1981·Journal - American Intra-Ocular Implant Society·C F Bahn, A Sugar
Aug 24, 2006·Clinical & Experimental Ophthalmology·Rasik B VajpayeeRadhika Tandon
Jul 1, 1984·Survey of Ophthalmology·D J AppleR J Olson
Nov 1, 1989·Australian and New Zealand Journal of Ophthalmology·A M BrooksW E Gillies
Nov 1, 1985·Australian and New Zealand Journal of Ophthalmology·I F RobertsonW G Campbell
Jan 1, 1990·Eye·S J Tuft, D J Coster
Nov 30, 2006·Cornea·Raja NarayananM Cristina Kenney
May 22, 2010·Cornea·Kátia Mantovani BottósHelena B Nader
Jan 1, 1990·Journal of Cataract and Refractive Surgery·M S Insler, R G Robbins
Mar 1, 1990·Journal of Cataract and Refractive Surgery·F W Price, W E Whitson
Apr 21, 1998·Survey of Ophthalmology·A N CarlsonP C Tso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.